Over the recent years we have seen a rapid increase in published research both in the preclinical and clinical field regarding the treatment of prostate cancer.
Only within the last two years the results of four positive phase III trials, all showing improved survival for patients with metastatic castration resistant prostate cancer (mCRPC), have been presented. In this article the basis of treatment of localized and advanced prostate cancer is discussed with a focus on new treatment options. Due to the rapid evolution of options an interdisciplinary management of patients with prostate cancer has become crucial in order to offer the best treatment to the patients.
Written by:
Merki R, Cathomas R. Are you the author?
Departement Innere Medizin, Abteilung für Onkologie und Hämatologie, Kantonsspital Graubünden, Chur.
Reference: Ther Umsch. 2012 Oct;69(10):585-90.
doi: 10.1024/0040-5930/a000334
PubMed Abstract
PMID: 23026884
Article in German.
